KRRO

Korro Bio, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001703647
$11.61 +10.26% $167.4M
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)5 New Institutional Positions
Vol
Market Cap$167.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders40 funds
Inst. Value$44.8M
Inst. Activity5 buys / 1 sells
Insider Activity19B / 2S
Insider Net $$44.8M
SEC Reports7
Press Releases1
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001703647·Prev Close $10.53

Recent Activity

Jun 11, 2026 SEC
A mixed institutional cluster in KRRO for Q3 2025 shows four buyers (led by Morgan Stanley doubling to $8.0M) adding $12
INST-CLUSTER — Impact 4/10
Jun 10, 2026 Insider
PEARSON TIMOTHY R was granted 14,677 shares
Director
Jun 10, 2026 Insider
FORMELA JEAN FRANCOIS was granted 14,677 shares
Director
Jun 10, 2026 Insider
Knobil Katharine was granted 14,677 shares
Director
Jun 2, 2026 SEC
Two insiders at Korro Bio, CEO Ram Aiyar and Director Jean Francois Formela, sold a combined $231K in open-market sales
CLUSTER — Impact 3/10
May 19, 2026 SEC
Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disease affe
8-K — Impact 6/10
Inst.
BALYASNY ASSET MANAGEMENT L.P. — NEW
1,040,054 shares ($11.8M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
136,227 shares ($1.5M)

Price Targets

$20.00 +72.3% upside Strong Buy
Current $11.61 Low $8.00 Median $21.50 High $30.00 10 analysts
$8.00 $30.00

Analyst Ratings

Strong Buy81% buy · 16 analysts
4Strong Buy
9Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 19, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
May 18, 2026 Citigroup INITIATE Buy
Mar 13, 2026 Cantor Fitzgerald MAINTAIN Overweight → Overweight
Mar 13, 2026 Raymond James UPGRADE Market Perform → Outperform
Feb 19, 2026 Clear Street UPGRADE Hold → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-1.28 ▲ +29.9% $-2.10 — $-0.66 53% YoY 9
Next Q $-1.27 ▲ +39.1% $-1.81 — $-0.68 34% YoY 9
Current FY $-5.18 ▲ +29.6% $-7.08 — $-3.20 41% YoY 9
Next FY $-5.04 ▲ +33.6% $-7.14 — $-3.47 3% YoY 8

Latest Reports

NEUTRAL INST-CLUSTER 4/10
A mixed institutional cluster in KRRO for Q3 2025 shows four buyers (led by Morgan Stanley doubling to $8.0M) adding $12
Jun 11, 2026
NEUTRAL CLUSTER 3/10
Two insiders at Korro Bio, CEO Ram Aiyar and Director Jean Francois Formela, sold a combined $231K in open-market sales
Jun 2, 2026
NEUTRAL Press 6/10
Korro Bio (KRRO) announced a $85 million PIPE financing led by Venrock Healthcare Capital Partners, with participation f
Mar 9, 2026

Top Institutional Holders

FundValueMove
BALYASNY ASSET MANAGEMENT L.P.$11.8MNEW
BlackRock, Inc.$5.2M—
DRIEHAUS CAPITAL MANAGEMENT LLC$5.1MEXIT
VANGUARD CAPITAL MANAGEMENT LLC$3.5M—
ADAGE CAPITAL PARTNERS GP,$2.6M—

Recent Insider Trades

DateInsiderTypeValue
Jun 10, 2026PEARSON TIMOTHYA$0.00
Jun 10, 2026FORMELA JEANA$0.00
Jun 10, 2026Knobil KatharineA$0.00
Jun 10, 2026Bermingham NessanA$0.00
Jun 10, 2026Meyers RachelA$0.00
40 institutional holders with $44.8M total value (3,965,756 shares) as of 2026-Q1. Top holders: BALYASNY, BlackRock,, DRIEHAUS. Net buying activity: 5 institutions added/increased vs 1 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1BALYASNY ASSET MANAGEMENT L.P.1,040,054$11.8M26.3%NEW
2BlackRock, Inc.460,006$5.2M11.6%—
3DRIEHAUS CAPITAL MANAGEMENT LLC450,045$5.1M11.4%EXIT -100.0%
4VANGUARD CAPITAL MANAGEMENT LLC310,913$3.5M7.9%—
5ADAGE CAPITAL PARTNERS GP, L.L.C.228,400$2.6M5.8%—
6CITADEL ADVISORS LLC168,700$1.9M4.3%TRIM -56.1%
7TWO SIGMA INVESTMENTS, LP165,472$1.9M4.2%ADD +75.4%
8VANGUARD PORTFOLIO MANAGEMENT LLC148,559$1.7M3.8%—
9STATE STREET CORP140,341$1.6M3.5%—
10RENAISSANCE TECHNOLOGIES LLC136,227$1.5M3.4%ADD +81.9%
11SUSQUEHANNA INTERNATIONAL GROUP, LLP117,000$1.3M3.0%—
12SUSQUEHANNA INTERNATIONAL GROUP, LLP87,100$986.0K2.2%—
13CITADEL ADVISORS LLC69,500$786.7K1.8%TRIM -56.1%
14Trexquant Investment LP56,208$636.3K1.4%ADD +83.3%
15GOLDMAN SACHS GROUP INC50,541$572.1K1.3%—
16RAYMOND JAMES FINANCIAL INC42,838$484.9K1.1%DOUBLED +357.6%
17VANGUARD FIDUCIARY TRUST CO41,541$470.2K1.1%—
18MORGAN STANLEY41,123$465.5K1.0%TRIM -41.0%
19FMR LLC38,900$440.3K1.0%NEAR_EXIT -93.3%
20MARSHALL WACE, LLP34,343$388.8K0.9%ADD +73.7%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
BALYASNY ASSET MANAGEMENT L.P.NEW—1,040,054—$11.8M2026-Q1
RENAISSANCE TECHNOLOGIES LLCADD74,900136,227+81.9%$1.5M2026-Q1
MORGAN STANLEYTRIM69,72841,123-41.0%$465.5K2026-Q1
MARSHALL WACE, LLPADD19,77234,343+73.7%$388.8K2026-Q1
CWM, LLCDOUBLED2889,772+3293.1%$110.6K2026-Q1
Allworth Financial LPDOUBLED1291+29000.0%$3.3K2026-Q1
RENAISSANCE TECHNOLOGIES LLCADD40,40074,900+85.4%$599.9K2025-Q4
MORGAN STANLEYTRIM167,49469,728-58.4%$558.5K2025-Q4
FMR LLCNEAR_EXIT563,68137,857-93.3%$303.2K2025-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INCTRIM23,10116,329-29.3%$130.8K2025-Q4
WELLS FARGO & COMPANY/MNADD5,1707,522+45.5%$60.3K2025-Q4
BANK OF AMERICA CORP /DE/ADD4,7045,896+25.3%$47.2K2025-Q4
Russell Investments Group, Ltd.DOUBLED8151,930+136.8%$15.5K2025-Q4
PNC FINANCIAL SERVICES GROUP, INC.TRIM2,914740-74.6%$5.9K2025-Q4
Allworth Financial LPNEAR_EXIT921-98.9%$9.002025-Q4
CWM, LLCNEAR_EXIT2,693288-89.3%$2.002025-Q4
Polar Capital Holdings PlcEXIT264,6940-100.0%$0.002025-Q4
Point72 Asset Management, L.P.EXIT531,9690-100.0%$0.002025-Q4
DRIEHAUS CAPITAL MANAGEMENT LLCEXIT671,9810-100.0%$0.002025-Q4
MORGAN STANLEYDOUBLED81,733167,494+104.9%$8.0M2025-Q3
CITADEL ADVISORS LLCTRIM350,646153,928-56.1%$7.4M2025-Q3
TWO SIGMA INVESTMENTS, LPADD36,74664,455+75.4%$3.1M2025-Q3
UBS Group AGDOUBLED18,58153,103+185.8%$2.5M2025-Q3
Trexquant Investment LPADD20,87038,260+83.3%$1.8M2025-Q3
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD17,77623,101+30.0%$1.1M2025-Q3
21 unique insiders with 36 transactions. Net insider value: $44.8M ($45.0M bought, $230.7K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 10, 2026PEARSON TIMOTHY RDirectorAWARD14,677——
Jun 10, 2026FORMELA JEAN FRANCOISDirectorAWARD14,677——
Jun 10, 2026Knobil KatharineDirectorAWARD14,677——
Jun 10, 2026Bermingham NessanDirectorAWARD14,677——
Jun 10, 2026Meyers RachelDirectorAWARD14,677——
Jun 10, 2026Behbahani AliDirectorAWARD14,677——
May 29, 2026Aiyar RamPresident and CEOSELL15,152$12.98$196.7K
May 28, 2026FORMELA JEAN FRANCOISDirectorSELL2,441$13.95$34.1K
May 26, 2026Aiyar RamPresident and CEOAWARD50,000$12.33$616.5K
Mar 31, 2026Lynx1 Capital Management LP10%+ OwnerBUY520$10.60$5.5K
Mar 10, 2026Mathers Edward T10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026Mathers Edward T10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026Makhzoumi Mohamad10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026Walker Paul Edward10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026SANDELL SCOTT D10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026Makhzoumi Mohamad10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026Walker Paul Edward10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026SANDELL SCOTT D10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026Behbahani AliDirectorAWARD242,945$11.11$2.7M
Mar 10, 2026Chang Carmen10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026Florence Anthony A. Jr.10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026Behbahani AliDirectorAWARD207,100$11.11$2.3M
Mar 10, 2026Chang Carmen10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026Florence Anthony A. Jr.10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026Yang Rick10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026New Enterprise Associates 17, L.P.10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026Yang Rick10%+ OwnerBUY207,100$11.11$2.3M
Mar 10, 2026New Enterprise Associates 17, L.P.10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026BASKETT FOREST10%+ OwnerBUY242,945$11.11$2.7M
Mar 10, 2026BASKETT FOREST10%+ OwnerBUY207,100$11.11$2.3M
Feb 2, 2026Cerio JeffreyGeneral CounselAWARD23,000——
Feb 2, 2026Dolan OliverSenior Vice President, FinanceAWARD15,000——
Feb 2, 2026Vincent Loic AChief Scientific OfficerAWARD35,000——
Feb 2, 2026Aiyar RamPresident and CEOAWARD40,000——
Feb 2, 2026Aiyar RamPresident and CEOAWARD80,000——
Feb 2, 2026Chappell ToddChief Operating OfficerAWARD38,000——
7 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 5.0/10.
NEUTRAL INST-CLUSTER 4/10
A mixed institutional cluster in KRRO for Q3 2025 shows four buyers (led by Morgan Stanley doubling
Jun 11, 2026
NEUTRAL CLUSTER 3/10
Two insiders at Korro Bio, CEO Ram Aiyar and Director Jean Francois Formela, sold a combined $231K i
Jun 2, 2026
BULLISH 8-K 6/10
Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a
May 19, 2026
NEUTRAL DEFA14A 3/10
Korro Bio, Inc. filed a definitive proxy statement for its 2025 annual meeting, where shareholders w
Apr 16, 2026
NEUTRAL EFFECT 4/10
Korro Bio, Inc. (KRRO) has had its Form S-3 shelf registration declared effective by the SEC, allowi
Mar 23, 2026
BEARISH S-3 7/10
Korro Bio has filed a shelf registration (S-3) to register the resale of up to 7,650,764 shares of c
Mar 13, 2026
BULLISH CLUSTER 8/10
Multiple insiders and institutional investors in Korro Bio (KRRO) collectively purchased over $20 mi
Mar 13, 2026
NEUTRAL 6/10
Korro Bio (KRRO) announced a $85 million PIPE financing led by Venrock Healthcare Capital Partners,
Mar 9, 2026
Current analyst consensus: Strong Buy (81% buy). Based on 16 analysts: 4 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$20.00 mean target +72.3% upside Strong Buy (3.00)
$8.00 Low $30.00 High
MetricValue
Current Price$11.61
Target Low$8.00
Target Mean$20.00
Target Median$21.50
Target High$30.00
# Analysts10
RecommendationStrong Buy (3.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-1.28 $-2.10 $-0.66 53.3% +29.9% 3↑ 2↓ $0.0B -88.6% 9
Next Q
2026-09-30
 $-1.27 $-1.81 $-0.68 33.9% +39.1% 3↑ 2↓ $0.0B -84.7% 9
Current FY
2026-12-31
 $-5.18 $-7.08 $-3.20 41.2% +29.6% 5↑ 2↓ $0.0B -92.2% 9
Next FY
2027-12-31
 $-5.04 $-7.14 $-3.47 2.6% +33.6% 0↑ 1↓ $0.0B -55.6% 8

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-1.279
7d ago$-1.176-0.103
30d ago$-1.824+0.545
60d ago$-1.824+0.545
90d ago$-2.011+0.733
9 analyst firms have rated this stock: 8 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 19, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
May 18, 2026 Citigroup INITIATE — Buy
Mar 13, 2026 Cantor Fitzgerald MAINTAIN Overweight Overweight
Mar 13, 2026 Raymond James UPGRADE Market Perform Outperform
Feb 19, 2026 Clear Street UPGRADE Hold Buy
Feb 17, 2026 William Blair UPGRADE Market Perform Outperform
Jan 29, 2026 Chardan Capital UPGRADE Neutral Buy
Jan 29, 2026 HC Wainwright & Co. UPGRADE Neutral Buy
Jan 29, 2026 Piper Sandler UPGRADE Neutral Overweight
Jan 28, 2026 Oppenheimer UPGRADE Perform Outperform
Jan 28, 2026 Cantor Fitzgerald UPGRADE Neutral Overweight

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264930081%
May 1, 20264930081%
Apr 1, 20264840075%
Mar 1, 20264840075%
Feb 1, 20263670056%
Jan 1, 202633100038%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 17, 2026
Clinical Trial
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
Phase Phase 2 — TERMINATED
May 15, 2026
other
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p>CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonu
May 7, 2026
earnings
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="justify">CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging
May 5, 2026
earnings_calendar
KRRO Q1 2026 Earnings Scheduled — 2026-05-05
Apr 16, 2026
other
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
<p align="justify">CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO),  a biopharmaceutical company develo
Apr 10, 2026
other
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
<p align="left">CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing
Mar 9, 2026
offering
Korro Announces Oversubscribed $85 Million Private Placement
<p align="left">CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing